Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2023-09-25 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a 'Current Report' pursuant to the Securities Exchange Act of 1934, dated September 25, 2023. The content describes an announcement of positive feedback from the FDA and includes a press release as an exhibit. There are no financial statements or detailed financial data included, only a description of an event and a press release. This type of filing is a regulatory announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-09-25 English
Delisting Announcement 2023
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 7, 2023, reporting a notice of non-compliance with Nasdaq listing rules due to the company's stock price falling below the minimum bid price requirement. The main content is about the company's receipt of a delisting warning and the compliance period to regain listing standards. This is a regulatory announcement about potential delisting, not a full financial report or earnings release. The key section is 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' Therefore, the document is best classified as a Delisting Announcement (DLST). The document length is over 5,000 characters and contains substantive information about the delisting notice, not just a brief announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of the delisting notice and Nasdaq rules referenced.
2023-09-07 English
Annual Report 2023
Annual Report Classification · 100% confidence The document is a prospectus supplement filed pursuant to Section 424(b)(3) related to a Registration Statement on Form S-1. It references and attaches the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and the Quarterly Report on Form 10-Q for the six months ended June 30, 2023. The text includes the full Form 10-K with detailed sections such as Business, Risk Factors, Management's Discussion and Analysis, Financial Statements, and Signatures, indicating it is the full annual report document. The document length is 15,000 characters, which is substantial and consistent with a full annual report. Therefore, the primary document type is the Annual Report (10-K).
2023-08-24 English
Director's Dealing 2023
Director's Dealing
2023-08-19 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2023, by Shuttle Pharmaceuticals Holdings, Inc. It reports the issuance of a press release providing a corporate update related to the filing of the Quarterly Report on Form 10-Q for the period ended June 30, 2023. The document itself does not contain the financial statements or substantive financial data but references the press release and the 10-Q filing. The length of the document is 3877 characters, which is relatively short and mainly serves as an announcement of the corporate update and the 10-Q filing. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full quarterly report or detailed financial data.
2023-08-15 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-08-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.